Evidence map›Paper›PMID 31272313›Full record

Trial reportJournal of the International Association of Providers of AIDS Care

Analysis of the Impact of Antiretroviral Drug Changes on Survival of Patients with Advanced-Stage AIDS with Multidrug-Resistant HIV Infection.

Rui Ma, Tae Hyun Jung, Peter N Peduzzi, Sheldon T Brown, Tassos C Kyriakides

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the International Association of Providers of AIDS Care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Rui Ma1 Department of Biostatistics, Yale University, New Haven, CT, USA.
Tae Hyun Jung1 Department of Biostatistics, Yale University, New Haven, CT, USA.
Peter N Peduzzi1 Department of Biostatistics, Yale University, New Haven, CT, USA.
Sheldon T Brown3 James J. Peters VA Medical Center, Bronx, NY, USA.
Tassos C Kyriakides2 VA Cooperative Studies Program Coordinating Center, West Haven, CT, USA.ORCID 0000-0001-8913-108X
Yale University · USJames J. Peters VA Medical Center · USProgram Support Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis article aims to elucidate the relationship between antiretroviral (ARV) medication changes and all-cause mortality using a total of 368 patients recruited from the United States (78%), United Kingdom (11%), and Canada (11%).

methodsData sources included demographic characteristics, ARV treatment history and modifications, and clinical biomarker data from the completed OPTions In Management with Antiretrovirals clinical trial. Descriptive analysis and graphical trajectory representation of ARV drug modifications and biomarker changes were undertaken. Three hypotheses aimed at assessing the impact of ARV modification parameters on clinical outcomes were tested. Kaplan-Meier survival techniques as well as Cox proportional hazard regression models were employed.

resultsResults from the analyses suggest that (1) switching therapy strategy from an intensified ARV regimen to a less intense one or vice versa, (2) having a moderate number (up to 2) of ARV drug changes per 6 months, and (3) changes based on clinical/HIV-related reasons or nonclinical reasons compared to ARV drug regimen changes due to clinical non-HIV reasons improved survival.

conclusionModifications in the ARV regimens of HIV-infected patients with multidrug resistance are associated with improved survival.

Indexed as

Drug Resistance, Multiple, ViralAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCanadaData Interpretation, StatisticalDrug SubstitutionFemaleHumansMaleMiddle AgedSurvival RateUnited KingdomUnited StatesViral LoadAnti-Retroviral Agentsall-cause mortalityantiretroviral therapydrug change

Identifiers

PMID31272313
PMCPMC6748500
OpenAlexW2953881185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.